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UNCERTAINTIES
What is the best treatment to reduce the need for
caesarean section in nulliparous women at term with
delayed first stage of labour?
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1Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK; 2Healthcare Sciences, Cardiff University, Cardiff CF24
0AB, UK; 3Birmingham Clinical Trials Unit, School of Cancer Sciences, Robert Aitken Institute, University of Birmingham, Birmingham; 4Birmingham
Women's and Children’s NHS Foundation Trust, Birmingham
Labour is commonly divided into three stages. The duration of
the first and second stages of labour vary, dependent on parity.
Figure 1⇓ depicts the stages of labour and expected duration as
defined by the National Institute for Health and Care Excellence
(NICE).1 Nulliparous women tend to have a longer labour than
multiparous women. Delay can result from poor uterine
contractions or the relationship between size, presentation, and
position of the fetus and the maternal pelvis that obstructs
vaginal delivery. Uterine contractile dysfunction affects between
11% and 30% of nulliparous women2-4 and is the focus of this
paper.
Delayed labour—There is some variation worldwide in the
definition of delayed labour (table 1⇓). The World Health
Organization considers delay as a rate of cervical dilation of
less than 0.5-1 cm in four hours once labour is established,
whereas NICE recommends waiting a further two hours with
cervical dilation of less than 1 cm before delay is confirmed.
Prolonged labour is associated with higher rates of
chorioamnionitis9 with risk of neonatal sepsis and of unplanned
caesarean section with associated risks of infection and
bleeding.10-12
Oxytocin—Treatment for a confirmed delay in labour is with
intravenous oxytocin1 5 to re-establish effective uterine
contractions. The dose is titrated against the strength and
frequency of uterine contractions by means of a variable rate
infusion pump and taking into account fetal wellbeing through
electronic fetal heart monitoring. Adverse effects include uterine
tachysystole and uterine hyperstimulation (see box 1 for
definitions), which are associated with hypoxic ischaemic
encephalopathy and neonatal death. Mother and baby therefore
need to be intensively monitored during treatment with oxytocin.
Injudicious use of oxytocin and inappropriate management
during labour have resulted in cases of fetal hypoxia and
resultant controversy around its use.13 There is no consensus on
the optimal dose regimen of oxytocin for delay in the first stage
of labour in nulliparous women at term (37-42 weeks’ gestation)
to reduce unplanned caesarean section and increase vaginal birth
with minimal adverse events. Recommendations are lacking
apart from in the UK (table 1⇓), and the regimens used vary
widely even within the same country,14 despite calls for a
standardised regimen.15
What is the evidence of uncertainty?
Limited evidence from randomised trials suggests that use of
oxytocin at a low dose shortens labour but does not affect
whether the baby is born normally, by means of instruments
(forceps or ventouse), or by caesarean section.1 16
With respect to the effectiveness of high dose regimens of
oxytocin, the Cochrane review17 published in 2013 (including
644 women, three randomised controlled trials, and one
quasi-randomised trial) compared high dose oxytocin regimens
with low dose regimens in women delayed in normal labour.
Because of variation in the dose regimens in the trials, the
authors defined high dose oxytocin as starting dose and
increments >4 mU/minute and low dose oxytocin as starting
dose 1-4 mU/minute and increments of 1-2 mU/minute. High
dose regimens were associated with a decrease in the rate of
caesarean section (risk ratio 0.62; 95% confidence interval 0.44
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What you need to know
• Prolonged labour is associated with adverse outcomes for mother and fetus, and intravenous oxytocin is the mainstay of treatment
• There is uncertainty as to the optimal regimen of oxytocin to decrease the chances of caesarean section with minimal adverse effects,
and there is some evidence that high dose regimens may be effective
• Administer oxytocin in hospital where the mother and baby can be closely monitored
Box 1: Definitions of terms used
Nulliparous—Woman who has not given birth before
Uterine tachysystole—Increased uterine contractions; >5 uterine contractions in 10 minutes for 20 minutes
Uterine hyperstimulation—Tachysystole with abnormal features of the fetal heart rate suggestive of hypoxia
to 0.86), although there was some doubt about this estimate
because of heterogeneity of treatment effect estimates (risk ratio
0.67; 0.38 to 1.18) under alternative model assumptions. The
only trial reporting length of labour17 included only 40 women
and reported a reduction with high dose of oxytocin (mean
difference −3.50 hours; 95% CI −6.38 to −0.62). Two of the
trials included both nulliparous and multiparous women, which
limits interpretation of findings. No differences were noted in
other maternal and neonatal outcomes or adverse effects.
There is uncertainty as to women’s views of the use of oxytocin,
with most trials focusing on clinical outcomes.18 Limited
qualitative evidence from interviews with women who
experienced prolonged labour suggests that intervention is
acceptable to women19 and that, in case of a delay, women
preferred to defer decision making to professionals.20
Is ongoing research likely to provide
relevant evidence?
No further trials have been reported since publication of the
Cochrane review, but several are ongoing. We searched the
WHO International Clinical Trials Registry Platform and
Clinicaltrials.gov in January 2017 and identified three ongoing
trials comparing low dose and high dose oxytocin for delay in
the first stage of labour in nulliparous women (see box 2 for
details).
These studies are likely to provide evidence on effectiveness
and safety of a high dose oxytocin regimen in delayed labour
to reduce duration of labour and improve chances of spontaneous
vaginal birth. The trials are taking place in America, Sweden,
and the UK.
Box 3 lists recommendations for further research.
What should we do in light of the
uncertainty?
Nulliparous women and women with a higher body mass index
have higher risk for slow progress in labour.21 At the antenatal
visit close to term, discuss with the woman and her partner the
expected duration and stages of labour and the possibility of
prolonged labour. Emphasise the importance of remaining
mobile and hydrated during labour. Explain that, if labour
progresses more slowly than expected, there is an increased
chance of infection and of requiring a caesarean section. At the
start of labour, inform the woman that progress of labour and
wellbeing of the fetus will be monitored throughout. Regular
vaginal examinations will be done to assess cervical dilatation.
As there is variation in the definitions of delay in labour, rely
on the relevant guidelines to make a diagnosis (table 1⇓).
Women with prolonged labour can opt to wait and see how
labour progresses without augmentation by oxytocin.
Intravenous oxytocin may be offered to strengthen uterine
contractions and accelerate progress, but there is only limited
evidence that this will increase the likelihood of spontaneous
delivery.
In case of a delay, offer pain relief and intravenous oxytocin
until the woman gives birth. Further evidence is required before
offering high dose oxytocin outside of a research setting.
Oxytocin should be given only where close monitoring of the
mother and fetus is possible and where adequate pain relief can
be given. If the woman is in labour outside an obstetric unit,
timely referral to a hospital for assessment and appropriate
intervention is recommended.
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Box 2: Ongoing randomised controlled trials comparing low dose oxytocin regimens with high dose regimens for
delay in the first stage of labour for nulliparous women
NCT01587625 OxyHighLow trial
Double blind randomised controlled trial of high dose versus low dose oxytocin for augmentation of delayed labour. Study start date
April 2012, recruitment due to be completed in December 2016
Setting and population—Three hospitals in southwest Sweden; 1376 nulliparous women at term in spontaneous active labour (regular
painful contractions, effaced cervix, dilated > 3-4 cm) whose progress is delayed defined with a 3 hour partogram action line
High dose regimen—Initial infusion 6.6 mU/minute increasing every 20 minutes by 6.6 mU to maximum of 59.4 mU/minute
Low dose regimen—Initial infusion 3.3 mU/minute increasing every 20 minutes by 3.3 mU to maximum of 29.7 mU/minute (this is the
recommended standard dose in Sweden)
Primary outcome—Caesarean section
NCT02487797
Randomized double blind clinical trial comparing oxytocin low dose and high dose regimens for labour augmentation. Study start date
September 2015, due to complete recruitment in June 2018
Setting and population—Northwestern Memorial Hospital, Prentice Women’s Hospital, Chicago, USA; 1002 nulliparous women >36
weeks pregnant with a singleton diagnosed with ≥6 regular uterine contractions within 60 minutes of observation, plus at least one of
the following: cervix ≥3 cm dilated or 80% effaced, or spontaneous rupture of membranes
High dose regimen—Initial infusion 6 mU/minute increasing every 15-30 minutes by 6 mU/minute
Low dose regimen—Initial infusion 2 mU/minute increasing every 15-30 minutes by 2 mU/minute
Primary outcome—Caesarean section
ISRCTN99841044, high or low dose Syntocinon for delay in labour (HOLDS)
Multicentre, randomised, double blind controlled trial. Recruitment due to start in March 2017 and be completed by August 2018. Trial
will be closed in May 2019
Setting and population—30 maternity units in UK; 1500 nulliparous women with confirmed delay in the first stage of labour and ruptured
membranes. Labour is established by regular, painful contractions and progressive cervical dilation from 4 cm. Delay is suspected when
cervical dilation is <2 cm in 4 hours once labour is established. Delay is confirmed by progress of <1 cm in 2 hours on repeat vaginal
examination
High dose regimen—Initial infusion 4mU/minute increasing every 30 minutes to maximum of 64 mU/minute
Low dose regimen—Initial infusion 2mU/minute increasing every 30 minutes to maximum of 32 mU/minute
Primary outcome—Caesarean section
Box 3: Recommendations for further research
Population—Nulliparous women with a singleton pregnancy at term with delayed progress in the first stage of spontaneous labour
Intervention—High dose regimens of oxytocin
Comparison—Low dose regimens of oxytocin
Outcome—Mode of birth (vaginal birth or caesarean section), safety, harms, duration of labour, women’s acceptability and satisfaction
Sources and selection criteria
We searched the websites of English speaking Colleges of Obstetricians and Gynaecologists internationally for definitions of normal and
delayed labour and treatment. We also searched WHO Guidelines and in the UK NICE guidelines (detailed in table 1⇓).
For evidence of effectiveness of oxytocin, we searched the Cochrane Database of Systematic Reviews and Clinical Evidence in January
2017 with search terms “delay in labour,” “augmentation,” “spontaneous vaginal birth,” and “caesarean section.” We found one Cochrane
review.
Education into practice
• What ideas does this article offer you on how better to describe normal labour, particularly to nulliparous women?
• Are you aware of how prolonged labour is managed in your local maternity setting ? What is usual practice?
• How could you best describe the management options for women with prolonged labour?
How patients were involved in the creation of this article
The patient representative on our research group highlighted the lack of evidence on women’s views on the experience of prolonged labour,
which we have included.
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Table
Table 1| Summary of professional guidelines for normal duration of labour, definition of delay in the first stage of labour, and recommended
treatment with oxytocin in nulliparous women
Recommended regimen of oxytocinDefinition of delay or prolonged labourNormal length of
labour
Professional organisation, year published
2 mU/min increasing every 30 minutes
to maximum of 32 mU/min
Suspected delay <2 cm dilation in 4 hours, with
delay confirmed with progress of <1 cm 2 hours
later
8-18 hoursNational Institute for Health and Care
Excellence (NICE), 20141
None detailed or recommended6 cm dilation with ≥4 hours of adequate
contractions or ≥6 hours of inadequate
contractions
<20 hoursAmerican College of Obstetricians and
Gynecologists, 20145
None detailed or recommendedDilation <1 cm/hour in active phase (period of
labour with dilatation of cervix from ~3–4 cm to 10
cm)
Not definedRoyal Australian and New Zealand College of
Obstetricians and Gynaecologists, 20146
None detailed or recommended<0.5-1 cm/hour during active phaseNot definedWorld Health Organization, 20147
None detailed or recommended<0.5 cm/hour over 4 hour periodNot definedSociety of Obstetricians and Gynaecologists of
Canada, 20168
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Figure
Fig 1 The three stages of labour and their expected duration1
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